Julie A. Stone

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

40h-index5.2kcitations134works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(20), Computational Drug Discovery Methods(19), Alzheimer's disease research and treatments(18), Cholinesterase and Neurodegenerative Diseases(17), Statistical Methods in Clinical Trials(16)

Publications133 total

Modeling amyloid plaque turnover dynamics improves characterization of drug effects
Alzheimer s & Dementia Translational Research & Clinical Interventions·2025Open Access
Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of <scp>COVID</scp>‐19
Clinical and Translational Science·2025Open Access
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study
Clinical Trials·2025· 1 citedOpen Access
Integrated Disease Chronicity Modeling to Map Longitudinal Biomarker Relationships in Alzheimer’s Disease
Alzheimer s & Dementia·2024Open Access
Mechanistic Disease Modeling to Inform Potential Strategies for Early Interventions with BACE inhibition
Alzheimer s & Dementia·2024Open Access
Mechanistic Model of Alzheimer’s Disease Progression: Linking Amyloid and Tau Pathologies
Alzheimer s & Dementia·2024Open Access
Molnupiravir: Mechanism of action, clinical, and translational science
Clinical and Translational Science·2024· 30 citedOpen Access
Development and application of a mechanistic model for Alzheimer’s Disease
2024Open Access
Joint Exposure‐Response Analysis of PET Amyloid Plaque Data from the BACE1 Inhibitor Verubecestat and Amyloid mAbs Trials in Prodromal to Moderate Alzheimer’s Disease
Alzheimer s & Dementia·2023Open Access
Pooled Modeling of Disease Progression in Two BACE1 Inhibitor Verubecestat Trials in Prodromal to Moderate Alzheimer’s Disease
Alzheimer s & Dementia·2023Open Access
Modeling and Simulation to Inform Potential New Strategies for BACEi in Treatment of Alzheimers Disease
Alzheimer s & Dementia·2023Open Access
Population pharmacokinetics of molnupiravir in adults with <scp>COVID</scp>‐19: Lack of clinically important exposure variation across individuals
CPT Pharmacometrics & Systems Pharmacology·2023· 10 citedOpen Access
Factors Influencing <scp>COVID</scp>‐19 Risk: Insights From Molnupiravir <scp>Exposure‐Response</scp> Modeling of Clinical Outcomes
Clinical Pharmacology & Therapeutics·2023· 9 citedOpen Access
Supplementary from Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
2023Open Access
Data from Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
2023Open Access
Supplementary from Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
2023Open Access
Data from Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
2023Open Access
Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach
EBioMedicine·2022· 10 citedOpen Access
Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease: A Series of N-of-1 Diet Trials
The American Journal of Gastroenterology·2022· 35 cited
An Investigation of Instability in Dried Blood Spot Samples for Pharmacokinetic Sampling in Phase 3 Trials of Verubecestat
The AAPS Journal·2022· 4 cited
page 1 of 7Next →

Frequent Co-authors

John A. Wagner(18), Larissa Wenning(13), Marian Iwamoto(13), Keith Gottesdiener(10), Paul Deutsch(8), Amelia S. Petry(7), Kenneth C. Lasseter(7), Sheila Breidinger(7), William D. Hanley(6), Sheng Bi(6), James Kost(6), Marissa F. Dockendorf(5), Gregory A. Winchell(5), Anna Kondic(5), Diana M. Brainard(5), Michael Hesney(4), Scott A. Waldman(4), Susan K. Bradshaw(4), Nicholas A. Kartsonis(4), David C. Turner(4)